{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:05:05Z","timestamp":1792695905269,"version":"4.5.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jogc.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Obstetrics and Gynaecology Canada"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jogc.2021.09.013","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T23:26:04Z","timestamp":1652397964000},"page":"527-536.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Guideline No. 422g: Menopause and Osteoporosis"],"prefix":"10.1016","volume":"44","author":[{"given":"Aliya A.","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajar Abu","family":"Alrob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalal S.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Dandurand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Wolfman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Fortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jogc.2021.09.013_bib0001","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1007\/s00198-016-3631-6","article-title":"The current economic burden of illness of osteoporosis in Canada","volume":"27","author":"Hopkins","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jogc.2021.09.013_bib0002","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00198-007-0426-9","article-title":"The care gap in diagnosis and treatment of women with a fragility fracture","volume":"19","author":"Bessette","year":"2008","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.jogc.2021.09.013_bib0003","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1701-2163(15)30489-8","article-title":"Menopause and Oseteoporosis Working Group. Osteoporosis in menopause","volume":"36","author":"Khan","year":"2014","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.jogc.2021.09.013_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jogc.2021.09.013_bib0005","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society* clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jogc.2021.09.013_bib0006","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1210\/clinem\/dgaa048","article-title":"Pharmacological management of osteoporosis in postmenopausal women: An endocrine society guideline update","volume":"105","author":"Shoback","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jogc.2021.09.013_bib0007","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(17)32640-5","article-title":"Screening in the community to reduce fractures in older women (SCOOP): A randomised controlled trial","volume":"391","author":"Shepstone","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jogc.2021.09.013_bib0008","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00198-017-4326-3","article-title":"Effectiveness of a two-step population-based osteoporosis screening program using FRAX: The randomized risk-stratified osteoporosis strategy evaluation (ROSE) study","volume":"29","author":"Rubin","year":"2018","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.jogc.2021.09.013_bib0009","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1002\/jbmr.3815","article-title":"The effect of a screening and treatment program for the prevention of fractures in older women: A randomized pragmatic trial","volume":"34","author":"Merlijn","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jogc.2021.09.013_bib0010","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2018.6537","article-title":"Screening to prevent osteoporotic fractures","volume":"319","author":"Viswanathan","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jogc.2021.09.013_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-011-9544-7","article-title":"FRAX\u00ae with and without bone mineral density","volume":"90","author":"Kanis","year":"2012","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jogc.2021.09.013_bib0012","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11657-013-0166-8","article-title":"Worldwide uptake of FRAX","volume":"9","author":"Kanis","year":"2014","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.jogc.2021.09.013_bib0013","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-011-1592-3","article-title":"High fracture probability with FRAX usually indicates densitometric osteoporosis: Implications for clinical practice","volume":"23","author":"Leslie","year":"2012","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.jogc.2021.09.013_bib0014","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00198-008-0588-0","article-title":"Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks","volume":"19","author":"Nguyen","year":"2008","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.jogc.2021.09.013_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107695","article-title":"External validation of the garvan nomograms for predicting absolute fracture risk: The troms\u00f8 study","volume":"9","author":"Ahmed","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jogc.2021.09.013_bib0016","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11606-018-4696-z","article-title":"Predicting fracture risk in younger postmenopausal women: Comparison of the garvan and FRAX risk calculators in the women's health initiative study","volume":"34","author":"Crandall","year":"2019","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jogc.2021.09.013_bib0017","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s00198-017-4134-9","article-title":"Validation of FRAX and the impact of self-reported falls among elderly in a general population: The HUNT study","volume":"28","author":"Hoff","year":"2017","journal-title":"Norway. Osteoporos Int."},{"key":"10.1016\/j.jogc.2021.09.013_bib0018","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00198-006-0290-z","article-title":"Influence of fall related factors and bone strength on fracture risk in the frail elderly","volume":"18","author":"Sambrook","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jogc.2021.09.013_bib0019","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/jbmr.2734","article-title":"A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX","volume":"31","author":"Mccloskey","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jogc.2021.09.013_bib0020","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00198-016-3741-1","article-title":"The added value of trabecular bone score to FRAX\u00ae to predict major osteoporotic fractures for clinical use in Chinese older people: The Mr. OS and Ms. OS cohort study in Hong Kong","volume":"28","author":"Su","year":"2017","journal-title":"Osteoporosis International"},{"key":"10.1016\/j.jogc.2021.09.013_bib0021","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jocd.2010.02.002","article-title":"Simplified 10-year absolute fracture risk assessment: A comparison of men and women","volume":"13","author":"Leslie","year":"2010","journal-title":"J Clin Densitom"},{"issue":"10117","key":"10.1016\/j.jogc.2021.09.013_bib0022","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet."},{"issue":"15","key":"10.1016\/j.jogc.2021.09.013_bib0023","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jogc.2021.09.013_bib0024","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bone.2017.08.018","article-title":"Determinants of short term fracture risk in patients with a recent history of low-trauma non-vertebral fracture","volume":"105","author":"Deloumeau","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.jogc.2021.09.013_bib0025","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jogc.2021.09.013_bib0026","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jogc.2021.09.013_bib0027","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1007\/s00198-014-2817-z","article-title":"Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: The TRIO study","volume":"25","author":"Paggiosi","year":"2014","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.jogc.2021.09.013_bib0028","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: Report of a task force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jogc.2021.09.013_bib0029","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jogc.2021.09.013_bib0030","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Postmenopausal osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jogc.2021.09.013_bib0031","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1056\/NEJMp1202623","article-title":"Continuing bisphosphonate treatment for osteoporosis \u2014 For whom and for how long?","volume":"366","author":"Black","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jogc.2021.09.013_bib0032","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.4146","article-title":"Role of bisphosphonate therapy in patients with osteopenia: A systemic review","author":"Iqbal","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.jogc.2021.09.013_bib0033","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture prevention with zoledronate in older women with osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jogc.2021.09.013_bib0034","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the fosit study","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.jogc.2021.09.013_bib0035","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures:results from the fracture intervention trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jogc.2021.09.013_bib0036","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00198-007-0493-y","article-title":"Effects of risedronate on fracture risk in postmenopausal women with osteopenia","volume":"19","author":"Siris","year":"2008","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.jogc.2021.09.013_bib0037","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/jbmr.3420","article-title":"Bisphosphonate drug holiday and fracture risk: A population-based cohort study","volume":"33","author":"Adams","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jogc.2021.09.013_bib0038","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00198-015-3145-7","article-title":"Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: The TRIO study","volume":"27","author":"Naylor","year":"2016","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.jogc.2021.09.013_bib0039","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1210\/jc.2006-1404","article-title":"Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: Evidence from a comparative metaanalysis of randomized controlled trials","volume":"92","author":"Boonen","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jogc.2021.09.013_bib0040","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00198-015-3386-5","article-title":"Calcium plus vitamin D supplementation and risk of fractures: An updated meta-analysis from the National Osteoporosis Foundation","volume":"27","author":"Weaver","year":"2016","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.jogc.2021.09.013_bib0041","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJMoa055218","article-title":"Calcium plus vitamin d supplementation and the risk of fractures","volume":"354","author":"Jackson","year":"2006","journal-title":"N Engl JMed"},{"key":"10.1016\/j.jogc.2021.09.013_bib0042","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00198-004-1734-y","article-title":"Alcohol intake as a risk factor for fracture","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jogc.2021.09.013_bib0043","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00198-004-1640-3","article-title":"Smoking and fracture risk: a meta-analysis","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jogc.2021.09.013_bib0044","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/1471-2474-13-177","article-title":"Effects of ground and joint reaction force exercise on lumbar spine and femoral neck bone mineral density in postmenopausal women: a meta-analysis of randomized controlled trials","volume":"13","author":"Kelley","year":"2012","journal-title":"BMC Musculoskelet Disord"},{"issue":"9","key":"10.1016\/j.jogc.2021.09.013_bib0045","doi-asserted-by":"crossref","first-page":"M599","DOI":"10.1093\/gerona\/57.9.M599","article-title":"Exercise and lumbar spine bone mineral density in postmenopausal women: a meta-analysis of individual patient data","volume":"57","author":"Kelley","year":"2002","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jogc.2021.09.013_bib0046","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.amjmed.2003.12.029","article-title":"Positive association between 25-hydroxy vitamin d levels and bone mineral density: A population-based study of younger and older adults","volume":"116","author":"Bischoff-Ferrari","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.jogc.2021.09.013_bib0047","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1210\/jc.2004-2364","article-title":"Prevalence of vitamin D inadequacy among postmenopausal north american women receiving osteoporosis therapy","volume":"90","author":"Holick","year":"2005","journal-title":"J Clin EndocrinolMetab"},{"key":"10.1016\/j.jogc.2021.09.013_bib0048","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1007\/s00198-011-1868-7","article-title":"The 25(OH)D level needed to maintain a favorable bisphosphonate response is \u226533 ng\/mL","volume":"23","author":"Carmel","year":"2012","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.jogc.2021.09.013_bib0049","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/jamainternmed.2015.3874","article-title":"Treatment of vitamin D insufficiency in postmenopausal women","volume":"175","author":"Hansen","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jogc.2021.09.013_bib0050","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1001\/jama.2010.594","article-title":"Annual high-dose oral vitamin D and falls and fractures in older women","volume":"303","author":"Sanders","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jogc.2021.09.013_bib0051","doi-asserted-by":"crossref","first-page":"E610","DOI":"10.1503\/cmaj.080663","article-title":"Vitamin D in adult health and disease: A review and guideline statement from Osteoporosis Canada","volume":"182","author":"Hanley","year":"2010","journal-title":"CMAJ"},{"key":"10.1016\/j.jogc.2021.09.013_bib0052","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.maturitas.2014.07.005","article-title":"The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: A consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)","volume":"79","author":"Rizzoli","year":"2014","journal-title":"Maturitas"},{"key":"10.1016\/j.jogc.2021.09.013_bib0053","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00223-009-9323-x","article-title":"Gastric and esophagus events before and during treatment of osteoporosis","volume":"86","author":"Vestergaard","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jogc.2021.09.013_bib0054","first-page":"42","article-title":"European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4\u2013G5d","volume":"36","author":"Evenepoel","year":"2021","journal-title":"Nephrol DialTransplant"},{"key":"10.1016\/j.jogc.2021.09.013_bib0055","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: A randomized extension to the horizon-pivotal fracture trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jogc.2021.09.013_bib0056","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1210\/jc.2014-1971","article-title":"Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: When is it reasonable to discontinue treatment?","volume":"99","author":"Cosman","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jogc.2021.09.013_bib0057","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/jbmr.403","article-title":"Effects of denosumab on fracture and bone mineral density by level of kidney function","volume":"26","author":"Jamal","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jogc.2021.09.013_bib0058","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jogc.2021.09.013_bib0059","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: A post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jogc.2021.09.013_bib0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of denosumab therapy for osteoporosis: A systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.jogc.2021.09.013_bib0061","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jogc.2021.09.013_bib0062","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jogc.2021.09.013_bib0063","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1359\/jbmr.081215","article-title":"Sequential treatment of severe postmenopausal osteoporosis after teriparatide: Final results of the randomized, controlled European study of forsteo (EUROFORS)*","volume":"24","author":"Eastell","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jogc.2021.09.013_bib0064","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.mayocp.2016.10.009","article-title":"Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: Results of the ACTIVExtend Trial","volume":"92","author":"Cosman","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jogc.2021.09.013_bib0065","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bone.2017.03.006","article-title":"Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The denosumab and teriparatide follow-up study (data-follow-up)","volume":"98","author":"Leder","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.jogc.2021.09.013_bib0066","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2018.09.020","article-title":"Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis","volume":"120","author":"D\u00edez-P\u00e9rez","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.jogc.2021.09.013_bib0067","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1\u201384) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jogc.2021.09.013_bib0068","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): Extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jogc.2021.09.013_bib0069","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"Activextend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jogc.2021.09.013_bib0070","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/jbmr.3427","article-title":"FRAME study: The foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab","volume":"33","author":"Cosman","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jogc.2021.09.013_bib0071","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jogc.2021.09.013_bib0072","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jbmr.2932","article-title":"Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass","volume":"32","author":"Genant","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jogc.2021.09.013_bib0073","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: A randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jogc.2021.09.013_bib0074","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jogc.2021.09.013_bib0075","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1359\/jbmr.070904","article-title":"Effects of raloxifene on fracture risk in postmenopausal women: The raloxifene use for the heart trial","volume":"23","author":"Ensrud","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jogc.2021.09.013_bib0076","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00198-011-1691-1","article-title":"Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: Results of a 5-year, randomized, placebo-controlled study","volume":"23","author":"Silverman","year":"2012","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.jogc.2021.09.013_bib0077","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.fertnstert.2009.02.093","article-title":"Efficacy of tissue-selective estrogen complex of bazedoxifene\/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women","volume":"92","author":"Lindsay","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jogc.2021.09.013_bib0078","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0140-6736(13)60140-3","article-title":"Selective oestrogen receptor modulators in prevention of breast cancer: An updated meta-analysis of individual participant data","volume":"381","author":"Cuzick","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jogc.2021.09.013_bib0079","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jogc.2021.09.013_bib0080","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/GME.0000000000000419","article-title":"A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: Effects on bone density and fracture","volume":"22","author":"Palacios","year":"2015","journal-title":"Menopause"},{"key":"10.1016\/j.jogc.2021.09.013_bib0081","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes:the nsabp study of tamoxifen and raloxifene (STAR) P-2 trial","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jogc.2021.09.013_bib0082","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Effects of estrogen plus progestin on risk of fracture and bone mineral density: the women's health initiative randomized trial","volume":"290","author":"Cauley","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jogc.2021.09.013_bib0083","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0378-5122(00)00158-4","article-title":"Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women \u2014 results of the danish osteoporosis prevention study","volume":"36","author":"Mosekilde","year":"2000","journal-title":"Maturitas"},{"key":"10.1016\/j.jogc.2021.09.013_bib0084","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women's health initiative randomized trials","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jogc.2021.09.013_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jogc.2021.09.013_bib0086","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.160450","article-title":"Atypical femoral fracture","volume":"189","author":"Khan","year":"2017","journal-title":"CMAJ"},{"key":"10.1016\/j.jogc.2021.09.013_bib0087","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/jbmr.1719","article-title":"Incidence of atypical nontraumatic diaphyseal fractures of the femur","volume":"27","author":"Dell","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jogc.2021.09.013_bib0088","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.carj.2014.01.002","article-title":"Atypical femoral fractures: A teaching perspective","volume":"66","author":"Khan","year":"2015","journal-title":"Can Assoc Radiol J"},{"key":"10.1016\/j.jogc.2021.09.013_bib0089","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","article-title":"Bisphosphonate use and atypical fractures of the femoral shaft","volume":"364","author":"Schilcher","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jogc.2021.09.013_bib0090","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/jbmr.3081","article-title":"Responses to treatment with teriparatide in patients with atypical femur fractures previously treated with bisphosphonates","volume":"32","author":"Watts","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jogc.2021.09.013_bib0091","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.bone.2012.10.006","article-title":"Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy","volume":"52","author":"Chiang","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.jogc.2021.09.013_bib0092","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00774-014-0617-3","article-title":"Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: A comparison between treatment with and without teriparatide","volume":"33","author":"Miyakoshi","year":"2015","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.jogc.2021.09.013_bib0093","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jogc.2021.09.013_bib0094","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jocd.2016.09.005","article-title":"Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the International Task Force on ONJ","volume":"20","author":"Khan","year":"2017","journal-title":"J Clin Densitom"}],"container-title":["Journal of Obstetrics and Gynaecology Canada"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1701216321007490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1701216321007490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T18:03:51Z","timestamp":1716833031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1701216321007490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":94,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1701216321007490"],"URL":"https:\/\/doi.org\/10.1016\/j.jogc.2021.09.013","relation":{},"ISSN":["1701-2163"],"issn-type":[{"value":"1701-2163","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guideline No. 422g: Menopause and Osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Obstetrics and Gynaecology Canada","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jogc.2021.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Society of Obstetricians and Gynaecologists of Canada\/La Soci\u00e9t\u00e9 des obst\u00e9triciens et gyn\u00e9cologues du Canada. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}